October 17, 2025

BioMed X launches Women’s Health R&D Accelerator in Heidelberg

BioMed X launches Women’s Health R&D Accelerator in Heidelberg
  • The first XFem Labs research project, supported by the Gates Foundation, aims to accelerate the development of non-hormonal contraceptives, in particular for women in low- and middle-income countries via BioMed X’s global talent sourcing and incubation model.

Heidelberg, Germany, October 14th, 2025. BioMed X, today announced the launch of XFem Labs, a new Women’s Health R&D Accelerator in Heidelberg. The purpose of this initiative, which is supported by the Gates Foundation, is to establish a world-class women’s health innovation hub that advances early-stage research into scalable solutions for women in need around the world, including low- and middle-income countries.

Embedded within the academic environments of the University of Heidelberg and Yale, and directly within R&D campuses of leading pharmaceutical companies, BioMed X bridges the translational gap between academia and industry to drive transformative innovation.

The first project at the new XFem Labs accelerator in Heidelberg is entitled “New Strategies for Female-Controlled Non-Hormonal Contraception”. Despite the availability of various contraceptive methods, 257 million women worldwide still face significant barriers to access. Current hormonal contraceptives are often associated with side effects, such as changes in bleeding patterns, resulting in high discontinuation rates. Non-hormonal, female-controlled alternatives remain limited and often challenging, hence there is an urgent need for new options.

The first XFem Labs call for application invites proposals that explore new biological targets, molecular mechanisms, or delivery modalities for continuous and/or on-demand non-hormonal contraception. Selected researchers will participate in a boot camp at BioMed X, resulting in the incubation of a new research team based In Heidelberg.

“Our joint goal with the Gates Foundation is to create a significant impact on the lives and health of women world-wide,” said Dr. Christian Tidona, CEO of BioMed X. “Together with an international network of top experts and key opinion leaders, we will jointly build and mentor new outstanding research teams who will strive to solve some of the most pressing challenges in women’s health.”

Researchers interested in becoming part of this new research group are invited to respond to this international call by submitting a project proposal via the BioMed X Career Space at https://career.bmedx.com/call/2025-XFL-C01 before December 7, 2025.

This first XFem Labs project is made possible with a $2 million grant and network support from the Gates Foundation.

Our latest News

discover more
Professor Dr. Hanns-Peter Knaebel has been appointed Director of Medicine at the Heidelberg and Mannheim University Hospitals Network

Professor Dr. Hanns-Peter Knaebel has been appointed Director of Medicine at the Heidelberg and Mannheim University Hospitals Network

Effective June 1, 2026, the Supervisory Board has appointed Hanns-Peter Knaebel, Chairman of the Executive Board, to serve as Chief Medical Officer. This move will ensure that the dynamic phase of medical strategy development and transformation within the group is overseen and managed centrally by the full Executive Board. Full Text in German below. Professor […]

ProtaGene Announces Strategic Partnership with the Life Science business of Merck to Expand Comprehensive Biologics Testing Solutions

ProtaGene Announces Strategic Partnership with the Life Science business of Merck to Expand Comprehensive Biologics Testing Solutions

HEILBRONN, Germany, May 14, 2026 – ProtaGene today announced a strategic partnership with the Life Science business of Merck, which operates as MilliporeSigma in the United States and Canada, to provide biopharmaceutical customers with an end-to-end testing solution across the entire biopharmaceutical product lifecycle, from early-stage development through GMP release testing. ProtaGene’s expertise in advanced protein […]

Universität Heidelberg Successful with Application for Collaborative Research Centre

Universität Heidelberg Successful with Application for Collaborative Research Centre

DFG funds extended CRC with approximately 17.4 million euros Heidelberg University has been successful in the latest approval round of the German Research Foundation (DFG) with a grant application for a major research consortium: The Collaborative Research Centre “Molecular Circuits of Heart Disease” (CRC 1550), based at the Medical Faculty Heidelberg, is entering a second […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp